Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Subject collections
    • Interviews
    • Alerts
  • About us
    • About DMM
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Workshops and Meetings
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Outstanding paper prize
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Alerts
  • Contact
    • Contact DMM
    • Advertising
    • Feedback
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

User menu

  • Log in

Search

  • Advanced search
Disease Models & Mechanisms
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

supporting biologistsinspiring biology

Disease Models & Mechanisms

Advanced search

RSS   Twitter   Facebook   YouTube

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Subject collections
    • Interviews
    • Alerts
  • About us
    • About DMM
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Workshops and Meetings
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Outstanding paper prize
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Alerts
  • Contact
    • Contact DMM
    • Advertising
    • Feedback
Commentary
Mouse models of allergic asthma: acute and chronic allergen challenge
Anthony T. Nials, Sorif Uddin
Disease Models & Mechanisms 2008 1: 213-220; doi: 10.1242/dmm.000323
Anthony T. Nials
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sorif Uddin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & tables
  • Info & metrics
  • PDF
Loading

Abstract

Asthma is defined as a chronic inflammatory disease of the airways; however, the underlying physiological and immunological processes are not fully understood. Animal models have been used to elucidate asthma pathophysiology, and to identify and evaluate novel therapeutic targets. Several recent review articles (Epstein, 2004; Lloyd, 2007; Boyce and Austen, 2005; Zosky and Sly, 2007) have discussed the potential value of these models. Allergen challenge models reproduce many features of clinical asthma and have been widely used by investigators; however, the majority involve acute allergen challenge procedures. It is recognised that asthma is a chronic inflammatory disease resulting from continued or intermittent allergen exposure, usually via inhalation, and there has been a recent focus on developing chronic allergen exposure models, predominantly in mice. Here, we review the acute and chronic exposure mouse models, and consider their potential role and impact in the field of asthma research.

INTRODUCTION

Human allergic asthma is defined as a chronic inflammatory disorder of the airways and is characterised by airway inflammation, persistent airways hyperresponsiveness (AHR) and intermittent, reversible airways obstruction (GINA, 2006; Bousquet et al., 2000). In addition, structural changes in the airway including subepithelial and airway wall fibrosis, goblet cell hyperplasia/metaplasia, smooth muscle thickening and increased vascularity are observed (Bousquet et al., 2000; Fish, 1999). These changes are termed ‘airway remodelling’ and may be the result of repeated exposure to the allergen, which causes repeated or continuing inflammation in the airways (Zosky and Sly, 2007). Chronic inflammation and structural changes are thought to have functional consequences that contribute to asthma symptoms.

The exact cellular and biochemical processes underlying chronic inflammation and airway remodelling are poorly understood. Although the best approach to investigate these processes, and to identify crucial pathways and potential novel targets for drug therapy, is to perform studies in human asthmatics, the required mechanistic studies are not acceptable owing to ethical reasons. Animal models provide an alternative for investigating disease mechanisms and progression. Because asthma is a complex multifactorial disease, it is unlikely that a single animal model of asthma that replicates all of the morphological and functional features of the chronic human disease will ever be developed. However, we can use animals to model specific features of the disease, and much of our current understanding of disease processes in asthma, and in particular the response to allergens, comes from studies in laboratory animals such as guinea pigs, rats and mice. The mouse is the most widely used species, mainly because of the availability of transgenic animals and because of the wide array of specific reagents that are available for analysis of the cellular and mediator response. This Commentary will, therefore, focus on the development of allergen challenge models in the mouse.

ACUTE ALLERGEN CHALLENGE MODELS

Mice do not spontaneously develop asthma; so, in order to investigate the processes underlying this disease, an artificial asthmatic-like reaction has to be induced in the airways. Mouse models of the acute allergic response to inhaled allergens have been widely used to elucidate the mechanisms underlying the immunologic and inflammatory responses in asthma, and for the identification and investigation of novel targets for controlling allergic inflammation.

A variety of different acute allergen challenge models have been developed in mice and a number of sensitisation and challenge protocols have been employed. Some of these are summarised in Table 1.

View this table:
  • View inline
  • View popup
Table 1

Mouse models of acute allergic pulmonary inflammation

The nature of the acute inflammatory model may be influenced by the choice of mouse strain, the allergen, and the sensitisation and challenge protocol (Zosky and Sly 2007; Kumar et al., 2008). The most commonly used strain of mouse for antigen challenge models is BALB/c as they develop a good T helper cell 2 (Th2)-biased immunological response (Boyce and Austen, 2005). However, other strains (C57BL/6 and A/J) have been used successfully in allergen challenge studies (Kumar et al., 2008). Ovalbumin (OVA) derived from chicken egg is a frequently used allergen that induces a robust, allergic pulmonary inflammation in laboratory rodents. A review of OVA challenge models has recently been published by Kumar et al. (Kumar et al., 2008). OVA, however, is seldom implicated in human asthma, and other groups have used alternative allergens that may have greater clinical relevance, for example house dust mite (HDM) and cockroach extracts (Johnson et al., 2004; Sarpong et al., 2003).

Although many different sensitisation and challenge protocols have been used, the basic model is consistent. Acute sensitisation protocols usually require multiple systemic administration of the allergen in the presence of an adjuvant. Adjuvants such as aluminium hydroxide (AlOH3) are known to promote the development of the Th2 phenotype by the immune system when it is exposed to an antigen. Adjuvant-free protocols have also been described (Blyth et al., 1996), but these usually require a greater number of exposures to achieve suitable sensitisation. Sensitisation solely via the airways has also been attempted using both OVA and HDM. With OVA models, success has been limited and only modest pulmonary inflammation and mild AHR have been observed. This might be because tolerance can develop when model protein antigens are delivered via inhalation without systemic sensitisation. Inhaled delivery of HDM has been more successful, possibly because of the intrinsic enzymatic activity of this allergen. After the sensitisation period (usually 14–21 days), the animal is challenged with the allergen via the airway, usually over a period of several days. Allergen may be inhaled as a nebulised formulation (aerosol), or administered by intratracheal (i.t.) or intranasal (i.n.) instillation of an aqueous formulation.

The acute challenge mouse models reproduce many key features of clinical asthma, for example elevated levels of IgE, airway inflammation, goblet cell hyperplasia, epithelial hypertrophy, AHR to specific stimuli and, in some models, early- and late-phase bronchoconstriction in response to allergen challenge. However, there are also some major differences. In acute challenge models, the pattern and distribution of pulmonary inflammation is different from that observed in individuals with asthma (Kumar and Foster, 2002). For example, bronchoalveolar lavage and histology studies indicate that the influx of inflammatory cells is dominated by eosinophils. Because of the short-term nature of the acute models, many of the lesions observed in chronic human asthma, such as chronic inflammation of the airway wall, and airway remodelling changes are absent. Furthermore, many of the key features appear to be short-lived and, in some models, airways inflammation and AHR have been shown to resolve within a few weeks after the final allergen challenge (McMillan and Lloyd, 2004).

Despite these apparent shortcomings, acute allergen challenge models have been successfully used to investigate disease processes, in particular the relationship between cells and inflammatory mediators, and how they orchestrate the inflammatory processes in the lung. Evidence supporting the hypothesis that asthma is a Th2-mediated disease, the role of the T cell in the allergic response, and the role of the eosinophil and its involvement in the development of AHR came from studies in the acute challenge models.

A wide range of cellular and molecular targets have been identified, and subsequently evaluated, in the acute challenge models. These include anti-cytokine approaches, specific mediator antagonists, monoclonal antibodies and specific enzyme inhibitors. With a number of these targets, efficacy has been demonstrated in the acute challenge models, but not in clinical trials in patients. Anti-IL-5 therapy is one of the most frequently discussed examples. IL-5 appears to have a key role in allergen-induced inflammatory responses and the development of AHR in mice. IL-5 knockout mice were protected both from acute allergic inflammation, AHR (Foster et al., 1996) and chronic airway remodelling (Cho, et al., 2004). However, IL-5 antagonists have been evaluated in both mild acute and chronic severe asthma, and have failed to show clinical benefit (Leckie et al., 2000; Kips et al., 2003). There are other examples of drugs that have shown efficacy in acute challenge models but not in clinical studies; these include VLA4 antagonists (Norris et al., 2005), PAF antagonists (Hozawa et al., 1995) and IL-4 antagonists (Riffo-Vasquez and Spina, 2002; Borish et al., 1999). One possible explanation for the contrasting data from the mouse and human studies is that in mouse acute challenge models it is only possible to assess the affect on the development of allergic responses; whereas with clinical studies, potential suppression of established inflammatory disease is investigated.

Thus, although the acute challenge models have been useful for investigating the process underlying acute airway inflammation and AHR, there are concerns relating to the suitability of acute challenge models for both the investigation of disease processes associated with chronic asthma, and assessing potential novel treatments that may slow, or reverse, the changes of airway inflammation and remodelling, and its effect on lung function.

CHRONIC ALLERGEN CHALLENGE MODELS

In order to address some of the issues associated with acute challenge models, several research groups have investigated chronic allergen exposure in mice. The key aims were to reproduce more of the features of clinical asthma, such as airway remodelling and persistent AHR, and to enable novel therapies to be evaluated in a therapeutic setting rather than a prophylactic setting, i.e. evaluating the effect of a novel drug in an established pulmonary inflammation setting. A number of different chronic challenge models have been developed by increasing the number of allergen challenges, some examples are shown in Table 2. Kumar et al. and Lloyd have discussed some of these models in recent review articles (Kumar et al., 2008; Lloyd, 2007).

View this table:
  • View inline
  • View popup
Table 2

Mouse models of chronic allergic pulmonary inflammation

Chronic allergen challenge models involve repeated exposure of the airways to low levels of allergen for periods of up to 12 weeks. Different allergens have been employed and co-administration of an adjuvant is not always required. A number of investigators, for example Temelkovski et al., Fernandez-Rodriguez et al. and Wegman have used OVA to establish a chronic exposure (Temelkovski et al., 1998; Fernandez-Rodriguez et al., 2008; Wegmann, 2008). Others have used environmentally relevant allergens such as HDM extract or grass pollen (Johnson et al., 2004; Kim et al., 2006). One anticipated problem with chronic allergen exposure, in particular with model protein antigens such as OVA, was that long-term challenge might lead to the development of tolerance and downregulation of inflammation and AHR (Jungsuwadee et al., 2004; Kumar et al., 2008). Both the strain of mouse and route of allergen administration are factors that may influence the induction of tolerance (McMillan and Lloyd, 2004; Shinagawa and Kojima, 2003). Kumar et al. suggested that tolerance might be related to the high mass concentrations of the aerosolised allergen used, which could overwhelm the clearance mechanisms (Kumar et al., 2008). This group successfully developed a model in which sensitised animals were exposed to inhalation of controlled mass concentrations of aerosolised antigen to minimise parenchymal inflammation and tolerance.

Chronic allergen exposure in mice has been shown to reproduce some of the hallmarks of human asthma including allergen-dependent sensitisation, a Th2-dependent allergic inflammation characterised by eosinophilic influx into the airway mucosa, and AHR. In addition, in some models, there is evidence of airway remodelling with goblet cell hyperplasia, epithelial hypertrophy, and either subepithelial or peribronchiolar fibrosis. Importantly, some of the key features of the chronic allergen exposure models have been shown to persist after the final challenge. After cessation of allergen challenge, some features of airway remodelling have been shown to persist in a number of models (Johnson et al., 2004; Macmillan and Lloyd, 2004; Kumar et al., 2004a). In these models, the persistence of AHR and lung inflammation varies depending on the exposure protocols employed (Lloyd, 2007).

There are limitations associated with the chronic models. In some cases, features peculiar to the mouse are observed that are not seen in human asthma. For example, in the mouse, inflammation is not restricted to the conducting airways, whereas it is in humans, and both lung parenchymal and vascular inflammation/remodelling are observed (Wenzel and Holgate, 2006). Large increases in airway smooth muscle, which is a characteristic feature of chronic asthma (Carroll et al., 1993), either does not appear to occur (Wenzel and Holgate, 2006) or, if it does, only after high level challenge (Shinagawa and Kojima, 2003; McMillan and Lloyd, 2004). Furthermore, there is little or no recruitment of mast cells into the airway wall or epithelium (Boyce and Austen, 2005), which may reflect the paucity of mast cells in the airways of mice (Kumar and Foster, 2002).

Despite these issues, using repetitive allergen provocation in mice has been shown to mimic important features of the human disease and would appear to represent an improvement over the acute challenge models.

IMPACT OF CHRONIC ALLERGEN CHALLENGE MODELS ON ASTHMA RESEARCH

Chronic allergen exposure in mice appears to now be the model of choice for studying the role of specific cell types and inflammatory cytokines and mediators in the processes involved in chronic inflammation and, in particular, some of the structural changes to the airways. For example, Humbles et al. have used a chronic challenge model to investigate the role of the eosinophil in airway remodelling (Humbles et al., 2004), and Kumar et al. and McMillan et al. have investigated the role of TGF-β in the development of airway remodelling in their chronic challenge model (Kumar et al., 2004a; McMillan et al., 2005). In addition, Yang et al. have used chronic models to investigate the role of IL-13 in regulating chronic inflammatory changes to the airway (Yang et al., 2005). These, and future, studies will add to our understanding of the mechanisms of chronic inflammation and airway remodelling and their contribution to asthma symptoms.

Chronic models may also provide a more suitable system for the preclinical evaluation of novel therapeutic agents. Unlike acute challenge models, the chronic challenge model enables investigations to be carried out in a setting of established airway inflammation and AHR and, therefore, more closely reflects most of the experimental studies undertaken in the clinic. A number of groups are using chronic models to profile established and novel pharmacological treatments for asthma. These studies might provide an insight into the predictive nature of the chronic models with regard to clinical outcome. A summary of some of the compounds that have been evaluated in mouse acute and chronic allergen challenge models and in human asthma trials is provided in Table 3. A number of anti-inflammatory agents are being profiled in chronic models, and reports of efficacy with corticosteroids (Macmillan et al., 2005), leukotriene receptor antagonists (Henderson et al., 2002) and phosphodiesterase 4 (PDE4) inhibitors (Herbert, et al., 2008) are emerging. Preliminary data suggest that certain chronic models might reproduce sensitivity to drug therapy in the clinic. However, further studies using a wider range of molecules, including examples that have demonstrated positive and negative outcomes in the clinic, are required. These studies will enable investigators to judge whether the chronic models might better reflect clinical outcome and represent an improvement over the acute challenge models.

View this table:
  • View inline
  • View popup
Table 3

Compounds developed, or in development, for the treatment of respiratory disease: profile in preclinical mouse models and in clinical studies

CONCLUSIONS

Mouse allergen challenge models are a basic, and frequently used, tool for asthma research. Because of the complexity and diverse nature of the disease, it is unlikely that a mouse model that is truly representative of clinical asthma will be developed. Efforts are focusing on modelling specific disease phenotypes rather than trying to reproduce all features of asthma in a single model. Acute allergen challenge models have been extensively used to investigate pulmonary inflammation and AHR, but their use is limited, in particular when relating findings to chronic asthma. Chronic allergen challenge models appear to reproduce some of the features of chronic asthma and might enable key questions, relating to both the pathogenesis of asthma and potential approaches to novel therapy, to be addressed. Both acute and chronic allergen challenge models have limitations that need to be taken into account when extrapolating findings from the animal model to the human disease.

It is important that mouse models are valid and reflect clinical asthma as closely as possible. Studies are ongoing to refine and improve existing models in order to enhance their utility. For example, asthma exacerbations account for the majority of asthma-related hospital visits and this is becoming a focus of research. Mouse models are being developed to model asthma exacerbations, and investigators are using acute and chronic allergen challenge models as a background for superimposing additional, higher intensity allergen challenge (Siegle et al., 2006; Ito et al., 2008) or viral infection (Bartlett et al., 2008).

A combination of improved animal models, which more closely reflect asthma, and use of relevant human systems will broaden our knowledge of the disease and help identify and evaluate new therapeutic targets.

Acknowledgements

Deposited in PMC for immediate release.

Footnotes

  • ↵1 Discovery Biology, Respiratory Centre of Excellence for Drug Discovery, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK

  • COMPETING INTERESTSThe authors declare no competing financial interests.

REFERENCES

    1. Alexander, A. G.,
    2. Barnes, N. C. and
    3. Kay, A. B.
    (1992). Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 339, 324–328.
    OpenUrlCrossRefPubMedWeb of Science
  1. ↵
    1. Bartlett, N. W.,
    2. Walton, R. P.,
    3. Edwards, M. R.,
    4. Aniscenko, J.,
    5. Caramori, G.,
    6. Zhu, J.,
    7. Glanville, N.,
    8. Choy, K. J.,
    9. Jourdan, P.,
    10. Burnet, J.,
    11. et al.
    (2008). Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat. Med. 14, 199–204.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Blyth, D. I.,
    2. Pedrick, M. S.,
    3. Savage, T. J.,
    4. Hessel, E. M. and
    5. Fattah, D.
    (1996). Lung inflammation and epithelial changes in a murine model of atopic asthma. Am. J. Respir. Cell Mol. Biol. 14, 425–438.
    OpenUrlCrossRefPubMedWeb of Science
    1. Blyth, D. I.,
    2. Wharton, T. F.,
    3. Pedrick, M. S.,
    4. Savage, T. J. and
    5. Sanjar, S.
    (2000). Airway subepithelial fibrosis in a murine model of atopic asthma, suppression by dexamethasone or anti-IL-5 antibody. Am. J. Respir. Cell Mol. Biol. 23, 241–246.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Borish, L. C.,
    2. Nelson, H. S.,
    3. Lanz, M. J.,
    4. Claussen, L.,
    5. Whitmore, J. B.,
    6. Agosti, J. M. and
    7. Garrison, L.
    (1999). Interleukin-4 receptor in moderate atopic asthma: a phase I/II randomized, placebo controlled trial. Am. J. Respir. Crit. Care Med. 160, 1816–1823.
    OpenUrlCrossRefPubMedWeb of Science
    1. Borish, L. C.,
    2. Nelson, H. S. and
    3. Corren, J.
    (2001). Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107, 963–970.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Bousquet, J.,
    2. Jeffery, P. K.,
    3. Busse, W. W.,
    4. Johnson, M. and
    5. Vignola, A. M.
    (2000). Asthma: from bronchoconstriction to airways inflammation and remodelling. Am. J. Respir. Crit. Care Med. 161, 1720–1745.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Boyce, J. A. and
    2. Austen, K. F.
    (2005). No audible wheezing: nuggets and conundrums from mouse asthma models. J. Exp. Med. 201, 1869–1873.
    OpenUrlAbstract/FREE Full Text
    1. Busse, W.,
    2. Corren, J.,
    3. Lanier, B. Q.,
    4. McAlary, M.,
    5. Fowler-Taylor, A.,
    6. Cioppa, G. D.,
    7. van As, A. and
    8. Gupta, N.
    (2001). Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184–190.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Carroll, N. G.,
    2. Elliot, J.,
    3. Morton, A. R. and
    4. James, A. L.
    (1993). The structure of large and small airways in nonfatal and fatal asthma. Am. Rev. Respir. Dis. 147, 405–410.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Cho, J. Y.,
    2. Miller, M.,
    3. Baek, K. J.,
    4. Han, J. W.,
    5. Nayar, J.,
    6. Lee, S. Y.,
    7. McElwain, K.,
    8. McElwain, S.,
    9. Friedman, S. and
    10. Broide, D. H.
    (2004). Inhibition of airway remodeling in IL-5 deficient mice. J. Clin. Invest. 13, 551–560.
    OpenUrl
    1. Choi, I. W.,
    2. Sun-Kim Kim, Y. S.,
    3. Ko, H. M.,
    4. Im, S. Y.,
    5. Kim, J. H.,
    6. You, H. J.,
    7. Lee, Y. C.,
    8. Lee, J. H.,
    9. Park, Y. M.,
    10. et al.
    (2005). TNF-a induces the late-phase airway hyperresponsiveness and airway inflammation through cytosolic phospholipase A2 activation. J. Allergy Clin. Immunol. 116, 537–543.
    OpenUrlCrossRefPubMedWeb of Science
    1. Deveci, F.,
    2. Muz, M. H.,
    3. Ilhan, N.,
    4. Kirkil, G.,
    5. Turgut, T. and
    6. Akpolat, N.
    (2008). Evaluation of the anti-inflammatory effect of infliximab in a mouse model of acute asthma. Respirology 13, 488–497.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Epstein, M. M.
    (2004). Do mouse models of allergic asthma mimic clinical disease? Int. Arch. Allergy Immunol. 133, 84–100.
    OpenUrlCrossRefPubMedWeb of Science
    1. Eum, S. Y.,
    2. Maghni, K.,
    3. Hamid, Q.,
    4. Campbell, H.,
    5. Eidelman, D. H. and
    6. Martin, J. G.
    (2003). Involvement of the cysteinyl-leukotrienes in allergen-induced airway eosinophilia and hyperresponsiveness in the mouse. Am. J. Respir. Cell Mol. Biol. 28, 25–32.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Fernandez-Rodriguez, S.,
    2. Ford, W. R.,
    3. Broadley, K. J. and
    4. Kidd, E. J.
    (2008). Establishing the phenotype in novel acute and chronic murine models of allergic asthma. Int. Immunopharmacol. 8, 756–763.
    OpenUrlPubMed
  10. ↵
    1. Fish, J. E. and
    2. Peters, S. P.
    (1999). Airway remodelling and persistent airways obstruction in asthma. J. Allergy Clin. Immunol. 104, 509–516.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Foster, P.,
    2. Hogan, S.,
    3. Ramsay, A.,
    4. Matthaei, K. and
    5. Young, I.
    (1996). Interleukin-5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 183, 195–201.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Foster, P. S.,
    2. Yang, M.,
    3. Herbert, C. and
    4. Kumar, R. K.
    (2002). CD4(+) T-lymphocytes regulate airway remodeling and hyper-reactivity in a mouse model of chronic asthma. Lab. Invest. 82, 455–462.
    OpenUrlPubMedWeb of Science
    1. Gauvreau, G. M.,
    2. Boulet, L.-P.,
    3. Fitzgerald, J. M.,
    4. Durn, B.,
    5. Zhou, S.,
    6. Burt, D.,
    7. Watson, R. M.,
    8. Duong, M.,
    9. Killian, K. J.,
    10. Carlsten, C.,
    11. et al.
    (2008). The effects of IMA-638 on allergen induced airway responses in subjects with mild atopic asthma. European Respiratory Society Meeting, Berlin. Eur. Resp. J. Abstract 827S. (in press).
  13. ↵
    Global initiative for asthma (GINA). 2006. http://www.ginaasthma.com
    1. Hamelmann, E.,
    2. Cieslewicz, G.,
    3. Schwarze, J.,
    4. Ishizuka, T.,
    5. Joetham, A.,
    6. Heusser, C. and
    7. Gelfand, E. W.
    (1999a). Anti-IL-5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 160, 934–941.
    OpenUrlCrossRefPubMedWeb of Science
    1. Hamelmann, E.,
    2. Tadeda, K.,
    3. Oshiba, A. and
    4. Gelfand, E. W.
    (1999b). Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness – a murine model. Allergy 54, 297–305.
    OpenUrlCrossRefPubMedWeb of Science
    1. Henderson, W. R. Jr.,
    2. Lewis, D. B.,
    3. Albert, R. K.,
    4. Zhang, Y.,
    5. Lamm, W. J.,
    6. Chianf, G. K.,
    7. Jones, F.,
    8. Eriksen, P.,
    9. Tien, Y. T.,
    10. Jonas, M.,
    11. et al.
    (1996). The importance of leukotrienes in airway inflammation in a mouse model of asthma. J. Exp. Med. 184, 1483–1494.
    OpenUrlAbstract/FREE Full Text
    1. Henderson, W. R. Jr.,
    2. Lu, J.,
    3. Poole, K. M.,
    4. Dietsch, G. N. and
    5. Chi, E. Y.
    (2000a). Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model. J. Immunol. 164, 3360–3367.
    OpenUrlAbstract/FREE Full Text
    1. Henderson, W. R. Jr.,
    2. Chi, E. Y. and
    3. Maliszewski, C. R.
    (2000b). Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J. Immunol. 164, 1086–1095.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Henderson, W. R.,
    2. Tang, L.,
    3. Chu, S.,
    4. Tsao, S. M.,
    5. Chiang, G. K.,
    6. Jones, F.,
    7. Jonas, M.,
    8. Pae, C.,
    9. Wang, H. and
    10. Chi, E. Y.
    (2002). A role for cysteinyl leukotrienes in airway remodelling in a mouse asthma model. Am. J. Respir. Crit. Care Med. 165, 108–116.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Herbert, C.,
    2. Hettiaratchi, A.,
    3. Webb, D. C.,
    4. Thomas, P. S.,
    5. Foster, P. S. and
    6. Kumar, R. K.
    (2008). Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma. Clin. Exp. Allergy 38, 847–856.
    OpenUrlCrossRefPubMedWeb of Science
    1. Hessel, E. M.,
    2. Zwart, A.,
    3. Oostveen, E.,
    4. Van Oosterhout, A. J.,
    5. Blyth, D. I. and
    6. Nijkamp, F. P.
    (1995). Repeated measurement of respiratory function and bronchoconstriction in unanesthetised mice. J. Appl. Physiol. 79, 1711–1716.
    OpenUrlAbstract/FREE Full Text
    1. Holgate, S. T.,
    2. Chuchalin, A. G.,
    3. Hébert, J.,
    4. Lötvall, J.,
    5. Persson, G. B.,
    6. Chung, K. F.,
    7. Bousquet, J.,
    8. Kerstjens, H. A.,
    9. Fox, H.,
    10. Thirlwell, J.,
    11. et al.
    (2004). Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy 34, 632–638.
    OpenUrlCrossRefPubMedWeb of Science
    1. Howarth, P. H.,
    2. Babu, K. S.,
    3. Arshad, H. S.,
    4. Lau, L.,
    5. Buckley, M.,
    6. McConnell, W.,
    7. Becket, P.,
    8. Al Ali, M.,
    9. Chauhan, A.,
    10. Wilson, S. J.,
    11. et al.
    (2005). Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60, 1012–1018.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Hozawa, S.,
    2. Hiruta, Y.,
    3. Ishioka, S. and
    4. Yamakido, M.
    (1995). Effects of a PAF antagonist, Y-24180 on bronchial hyperresponsiveness in patients with asthma. Am. J. Respir. Crit. Care Med. 152, 1198–1202.
    OpenUrlCrossRefPubMedWeb of Science
    1. Humbert, M.,
    2. Beasley, R.,
    3. Ayres, J.,
    4. Slavin, R.,
    5. Hébert, J.,
    6. Bousquet, J.,
    7. Beeh, K. M.,
    8. Ramos, S.,
    9. Canonica, G. W.,
    10. Hedgecock, S.,
    11. et al.
    (2005). Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60, 309–316.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Humbles, A. A.,
    2. Lloyd, C. M.,
    3. McMillan, S. J.,
    4. Friend, D. S.,
    5. Xanthou, G.,
    6. McKenna, E. E.,
    7. Ghiran, S.,
    8. Gerard, N. P.,
    9. Yu, C.,
    10. Orkin, S. H.,
    11. et al.
    (2004). A critical role for eosinophils in allergic airways remodeling. Science 305, 1776–1779.
    OpenUrlAbstract/FREE Full Text
    1. Israel, E.,
    2. Cohn, J.,
    3. Dubé, L. and
    4. Drazen, J. M.
    (1996). Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. Zileuton Clinical Trial Group. JAMA 275, 931–936.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Ito, K.,
    2. Herbert, C.,
    3. Siegle, J. S.,
    4. Vuppusetty, C.,
    5. Hansbro, N.,
    6. Thomas, P.,
    7. Foster, P.,
    8. Barnes, P. and
    9. Kumar, R.
    (2008). Steroid-resistant neutrophilic inflammation in a mouse model of an acute exacerbation of asthma. Am. J. Respir. Crit. Care Med. (in press).
    1. Janssen, E. M.,
    2. van Oosterhout, A. J. M.,
    3. Nijkamp, F. P.,
    4. van Eden, W. and
    5. Wauben, M. H.
    (2000). The efficacy of immunotherapy in an experimental murine model of allergic asthma is related to the strength and site of T cell activation during immunotherapy. J. Immunol. 165, 7207–7214.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Johnson, J. R.,
    2. Wiley, R. E.,
    3. Fattouh, R.,
    4. Swirski, F. K.,
    5. Gajewska, B. U.,
    6. Coyle, A. J.,
    7. Guttierrez-Ramos, J. C.,
    8. Ellis, R.,
    9. Inman, M. D. and
    10. Jordana, M.
    (2004). Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodelling. Am. J. Respir. Crit. Care Med. 169, 378–385.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Jungsuwadee, P.,
    2. Benkovsky, M.,
    3. Dekan, G.,
    4. Stingl, G. and
    5. Epstein, M. M.
    (2004). Repeated aerosol allergen exposure suppresses inflammation in B-cell deficient mice with established allergic asthma. Int. Arch. Allergy Immunol. 133, 126–134.
    OpenUrl
    1. Kanehiro, A.,
    2. Takeda, K.,
    3. Joetham, A.,
    4. Tomkinson, A.,
    5. Ikemura, T.,
    6. Irvin, C. G. and
    7. Gelfand, E. W.
    (2000). Timing of administration of anti-VLA-4 differentiates airway hyperresponsiveness in the central and peripheral airways in mice. Am. J. Respir. Crit. Care Med. 162, 1132–1139.
    OpenUrlCrossRefPubMedWeb of Science
    1. Kanehiro, A.,
    2. Ikemura, T.,
    3. Mäkelä, M. J.,
    4. Lahn, M.,
    5. Joetham, A.,
    6. Dakhama, A. and
    7. Gelfand, E. W.
    (2001). Inhibition of PDE4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am. J. Respir. Crit. Care Med. 163, 173–184.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Kim, C. H.,
    2. Ahn, J. H.,
    3. Kim, S. J.,
    4. Lee, S. Y.,
    5. Kim, Y. K.,
    6. Kim, K. H.,
    7. Moon, H. S.,
    8. Song, J. S.,
    9. Park, S. H. and
    10. Kwon, S. S.
    (2006). Co-administration of vaccination with DNA encoding T-cell epitope on the Der p and BCG inhibited airway remodelling in a murine model of chronic asthma. J. Asthma 43, 345–353.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Kips, J. C.,
    2. O’Connor, B. J.,
    3. Langley, S. J.,
    4. Woodcock, A.,
    5. Kerstjens, H. A.,
    6. Postma, D. S.,
    7. Danzig, M.,
    8. Cuss, F. and
    9. Pauwels, R. A.
    (2003). Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma; a pilot study. Am. J. Respir. Crit. Care Med. 167, 1655–1659.
    OpenUrlCrossRefPubMedWeb of Science
    1. Kon, O. M.,
    2. Sihra, B. S.,
    3. Compton, C. H.,
    4. Leonard, T. B.,
    5. Kay, A. B. and
    6. Barnes, N. C.
    (1998). Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 352, 1109–1113.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Kumar, R. K. and
    2. Foster, P. S.
    (2002). Modeling allergic asthma in mice: pitfalls and opportunities. Am. J. Respir. Cell Mol. Biol. 27, 267–272.
    OpenUrlCrossRefPubMedWeb of Science
    1. Kumar, R. K.,
    2. Herbert, C.,
    3. Thomas, P. S.,
    4. Wollin, L.,
    5. Beume, R.,
    6. Yang, M.,
    7. Webb, D. C. and
    8. Foster, P. S.
    (2003). Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J. Pharmacol. Exp. Ther. 307, 349–355.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Kumar, R. K.,
    2. Herbert, C. and
    3. Kasper, M.
    (2004a). Reversibility of airway inflammation and remodelling following cessation of antigenic challenge in a model of chronic asthma. Clin. Exp. Allergy 34, 1796–1802.
    OpenUrlCrossRefPubMedWeb of Science
    1. Kumar, R. K.,
    2. Herbert, C.,
    3. Webb, D. C.,
    4. Li, L. and
    5. Foster, P. S.
    (2004b). Effects of anticytokine therapy in a mouse model of chronic asthma. Am. J. Respir. Crit. Care Med. 170, 1043–1048.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Kumar, R. K.,
    2. Herbert, C. and
    3. Foster, P. S.
    (2008). The ‘classical’ ovalbumin challenge model of asthma in mice. Curr. Drug Targets 9, 485–494.
    OpenUrlPubMed
  26. ↵
    1. Leckie, M. J.,
    2. ten Brinke, A.,
    3. Khan, J.,
    4. Diamant, Z.,
    5. O’Connor, B. J.,
    6. Walls, C. M.,
    7. Mathur, A. K.,
    8. Cowley, H. C.,
    9. Chung, K. F.,
    10. Djukanovic, R.,
    11. et al.
    (2000). Effects of interleukin-5 blocking monoclonal antibody on eosinophils, airways hyerresponsiveness, and the late asthmatic response. Lancet 356, 2144–2148.
    OpenUrlCrossRefPubMedWeb of Science
    1. Lee, S. Y.,
    2. Kim, J. S.,
    3. Lee, J. M.,
    4. Kwon, S. S.,
    5. Kim, K. H.,
    6. Moon, H. S.,
    7. Song, J. S.,
    8. Park, S. H. and
    9. Kim, Y. K.
    (2008). Inhaled corticosteroid prevents the thickening of airway smooth muscle in murine model of chronic asthma. Pulm. Pharmacol. Ther. 21, 14–19.
    OpenUrlCrossRefPubMed
    1. Lee, Y. C.,
    2. Kim, S. H.,
    3. Seo, Y. B.,
    4. Rho, S. S. and
    5. Lee, J. C.
    (2006). Inhibitory effects of Actinidia polygama extract and cyclosporine A on OVA-induced eosinophilia and bronchial hyperresponsiveness in a murine model of asthma. Int. Immunopharmacol. 6, 703–713.
    OpenUrlPubMed
    1. Leigh, R.,
    2. Ellis, R.,
    3. Wattie, J.,
    4. Southam, D. S.,
    5. De Hoogh, M.,
    6. Gauldie, J.,
    7. O’Byrne, P. M. and
    8. Inman, M. D.
    (2002a). Dysfunction and remodeling of the mouse airway persist after resolution of acute allergen-induced airway inflammation. Am. J. Respir. Cell Mol. Biol. 27, 526–535.
    OpenUrlCrossRefPubMedWeb of Science
    1. Leigh, R.,
    2. Vethanayagam, D.,
    3. Yoshida, M.,
    4. Watson, R. M.,
    5. Rerecich, T.,
    6. Inman, M. D. and
    7. O’Byrne, P. M.
    (2002b). Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 166, 1212–1217.
    OpenUrlCrossRefPubMedWeb of Science
    1. Leigh, R.,
    2. Ellis, R.,
    3. Wattie, J. N.,
    4. Hirota, J. A.,
    5. Matthaei, K. I.,
    6. Foster, P. S.,
    7. O’Byrne, P. M. and
    8. Inman, M. D.
    (2004a). Type 2 cytokines in the pathogenesis of sustained airway dysfunction and airway remodeling in mice. Am. J. Respir. Crit. Care Med. 169, 860–867.
    OpenUrlCrossRefPubMedWeb of Science
    1. Leigh, R.,
    2. Ellis, R.,
    3. Wattie, J.,
    4. Donaldson, D. D. and
    5. Inman, M. D.
    (2004b). Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice? Am. J. Respir. Crit. Care Med. 170, 851–856.
    OpenUrlCrossRefPubMedWeb of Science
    1. Leigh, R.,
    2. Southam, D. S.,
    3. Ellis, R.,
    4. Wattie, J. N.,
    5. Sehmi, R.,
    6. Wan, Y. and
    7. Inman, M. D.
    (2004c). T-cell-mediated inflammation does not contribute to the maintenance of airway dysfunction in mice. J. Appl. Physiol. 97, 2258–2265.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Lloyd, C. M.
    (2007). Building better mouse models of asthma. Curr. Allergy Asthma Rep. 7, 231–236.
    OpenUrlPubMed
    1. Lloyd, C. M.,
    2. Gonzalo, J.,
    3. Nguyen, T.,
    4. Delaney, T.,
    5. Tian, J.,
    6. Oettgen, H.,
    7. Coyle, A. J. and
    8. Gutierrez-Ramos, J. C.
    (2000). Resolution of bronchial hyperresponsiveness and pulmonary inflammation is associated with IL-13 and tissue leukocyte apoptosis. J. Immunol. 166, 2033–2040.
    OpenUrl
    1. Louw, C.,
    2. Williams, Z.,
    3. Venter, L.,
    4. Leitchtl, S.,
    5. Schmid-Wirlitsch, C.,
    6. Bredenbroker, D. and
    7. Bardin, P. G.
    (2007). Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration 74, 411–417.
    OpenUrlCrossRefPubMed
  28. ↵
    1. McMillan, S. J. and
    2. Lloyd, C. M.
    (2004). Prolonged allergen challenge in mice leads to persistent airway remodelling. Clin. Exp. Allergy 34, 497–507.
    OpenUrlCrossRefPubMedWeb of Science
    1. McMillan, S. J.,
    2. Bishop, B.,
    3. Townsend, M. J.,
    4. McKenzie, A. N. and
    5. Lloyd, C. M.
    (2002). The absence of IL-9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. J. Exp. Med. 195, 51–57.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. McMillan, S. J.,
    2. Xanthou, G. and
    3. Lloyd, C. M.
    (2005). Therapeutic administration of Budesonide ameliorates allergen-induced airway remodelling. Clin. Exp. Allergy 35, 388–396.
    OpenUrlCrossRefPubMedWeb of Science
    1. Nagai, H.,
    2. Yamaguchi, S. and
    3. Tanaka, H.
    (1996). The role of interleukin-5 in allergic airway hyperresponsiveness in mice. Ann. N. Y. Acad. Sci. 796, 91–96.
    OpenUrlPubMed
  30. ↵
    1. Norris, V.,
    2. Choong, L.,
    3. Tran, D.,
    4. Corden, Z.,
    5. Boyce, M.,
    6. Arshad, H.,
    7. Holgate, S.,
    8. O’Connor, B.,
    9. Millet, S.,
    10. Miller, B.,
    11. et al.
    (2005). Effect of IVL745, a VLA-4 antagonist on allergen-induced bronchoconstriction in patients with asthma. J. Allergy Clin. Immunol. 116, 761–767.
    OpenUrlCrossRefPubMedWeb of Science
    1. Pearlman, D. S.,
    2. Noonan, M. J.,
    3. Tashkin, D. P.,
    4. Goldstein, M. F.,
    5. Hamedani, A. G.,
    6. Kellerman, D. J. and
    7. Schaberg, A.
    (1997). Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Ann. Allergy Asthma Immunol. 78, 356–362.
    OpenUrlPubMedWeb of Science
    1. Ravensberg, A. J.,
    2. Luijk, B.,
    3. Westers, P.,
    4. Hiemstra, P. S.,
    5. Sterk, P. J.,
    6. Lammers, J. W. and
    7. Rabe, K. F.
    (2006). The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma. Allergy 61, 1097–1103.
    OpenUrlCrossRefPubMed
    1. Reiss, T. F.,
    2. Altman, L. C.,
    3. Chervinsky, P.,
    4. Bewtra, A.,
    5. Stricker, W. E.,
    6. Noonan, G. P.,
    7. Kundu, S. and
    8. Zhang, J.
    (1996). Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J. Allergy Clin. Immunol. 98, 528–534.
    OpenUrlCrossRefPubMedWeb of Science
    1. Richter, M.,
    2. Cloutier, S. and
    3. Sirois, P.
    (2007). Endothelin, PAF and thromboxane A2 in allergic pulmonary hyperreactivity in mice. Prostaglandins Leukot. Essent. Fatty Acids 76, 299–308.
    OpenUrl
  31. ↵
    1. Riffo-Vasquez, Y. and
    2. Spina, D.
    (2002). Role of cytokines and chemokines in bronchial hyperresponsiveness and airway inflammation. Pharmacol. Ther. 94, 185–211.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Sarpong, S. B.,
    2. Zhang, L. and
    3. Kleeberger, S. R.
    (2003). A novel mouse model of experimental asthma. Int. Arch. Allergy Immunol. 132, 346–354.
    OpenUrlCrossRefPubMed
    1. Shi, H.,
    2. Yokoyama, A. and
    3. Kohno, N.
    (1998). Effect of thromboxane A2 inhibitors on allergic pulmonary inflammation in mice. Eur. Respir. J. 11, 624–629.
    OpenUrlAbstract
  33. ↵
    1. Shinagawa, K. and
    2. Kojima, M.
    (2003). Mouse model of airway remodelling: strain differences. Am. J. Respir. Crit. Care Med. 68, 959–967.
    OpenUrl
  34. ↵
    1. Siegle, J. S.,
    2. Hansbro, N.,
    3. Herbert, C.,
    4. Yang, M.,
    5. Foster, P. S. and
    6. Kumar, R. K.
    (2006). Airway hyperreactivity in exacerbation of chronic asthma is independent of eosinophilic inflammation. Am. J. Resp. Cell Mol. Biol. 35, 565–570.
    OpenUrlCrossRefPubMed
    1. Stenton, S. C.,
    2. Young, C. A.,
    3. Harris, A.,
    4. Palmer, J. B.,
    5. Hendrick, D. J. and
    6. Walters, E. H.
    (1992). The effect of GR32191 (a thromboxane receptor antagonist) on airway responsiveness in asthma. Pulm. Pharmacol. 5, 199–202.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Temelkovski, J.,
    2. Hogan, S. P.,
    3. Shepherd, D. P.,
    4. Foster, P. S. and
    5. Kumar, R. K.
    (1998). An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 53, 849–856.
    OpenUrlAbstract/FREE Full Text
    1. Tomkinson, A.,
    2. Duez, A.,
    3. Cieslewicz, G.,
    4. Pratt, J. C.,
    5. Joetham, A.,
    6. Shanafelt, M. C.,
    7. Gundel, R. and
    8. Gelfand, E. W.
    (2001). A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J. Immunol. 166, 5792–5800.
    OpenUrlAbstract/FREE Full Text
    1. Tournoy, K. G.,
    2. Kips, J. C.,
    3. Schou, C. and
    4. Pauwels, R. A.
    (2000). Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness. Clin. Exp. Allergy 30, 79–85.
    OpenUrlCrossRefPubMedWeb of Science
    1. Townley, R. G.,
    2. Eda, R.,
    3. Hopp, R. J.,
    4. Bewtra, A. K. and
    5. Gillen, M. S.
    (1994). The effect of RP 59227, a platelet-activating factor antagonist, against antigen challenge and eosinophil and neutrophil chemotaxis in asthmatics. J. Lipid Mediat. Cell Signal. 10, 345–353.
    OpenUrlPubMed
    1. Ulrich, K.,
    2. Hincks, J. S.,
    3. Walsh, R.,
    4. Wetterstrand, E. M.,
    5. Fidock, M. D.,
    6. Sreckovic, S.,
    7. Lamb, D. J.,
    8. Douglas, G. J.,
    9. Yeadon, M.,
    10. Perros-Huguet, C.,
    11. et al.
    (2008). Anti-inflammatory modulation of chronic airway inflammation in the murine house dust mite model. Pulm. Pharmacol. Ther. 21, 637–647.
    OpenUrlCrossRefPubMed
    1. Van Schalkwyk, E.,
    2. Strydom, K.,
    3. Williams, Z.,
    4. Venter, L.,
    5. Leichtl, S.,
    6. Schmid-Wirlitsch, C.,
    7. Bredenbröker, D. and
    8. Bardin, P. G.
    (2005). Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J. Allergy Clin. Immunol. 116, 292–298.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Wegmann, M.
    (2008). Animal models of chronic experimental asthma-strategies for the identification of new therapeutic targets. J. Occup. Med. Toxicol. 3, S4.
    OpenUrlPubMed
  37. ↵
    1. Wenzel, S. and
    2. Holgate, S. T.
    (2006). The mouse trap: it still yields few answers in asthma. Am. J. Respir. Crit. Care Med. 174, 1173–1175.
    OpenUrlCrossRefPubMedWeb of Science
    1. Wenzel, S.,
    2. Wilbraham, D.,
    3. Fuller, R.,
    4. Getz, E. B. and
    5. Longphre, M.
    (2007). Effect of an Interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370, 1422–1431.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Yang, G.,
    2. Li, L.,
    3. Volk, A.,
    4. Emmell, E.,
    5. Petley, T.,
    6. Giles-Komar, J.,
    7. Rafferty, P.,
    8. Lakshminarayanan, M.,
    9. Griswold, D. E.,
    10. Bugelski, P. J.,
    11. et al.
    (2005). Therapeutic dosing with an anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J. Pharmacol. Exp. Ther. 313, 8–15.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Zosky, G. R. and
    2. Sly, P. D.
    (2007). Animal models of asthma. Clin. Exp. Allergy 37, 973–988.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
Previous ArticleNext Article
Back to top
Previous ArticleNext Article

This Issue

 Download PDF

Email

Thank you for your interest in spreading the word on Disease Models & Mechanisms.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Mouse models of allergic asthma: acute and chronic allergen challenge
(Your Name) has sent you a message from Disease Models & Mechanisms
(Your Name) thought you would like to see the Disease Models & Mechanisms web site.
Share
Mouse models of allergic asthma: acute and chronic allergen challenge
Anthony T. Nials, Sorif Uddin
Disease Models & Mechanisms 2008 1: 213-220; doi: 10.1242/dmm.000323
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Mouse models of allergic asthma: acute and chronic allergen challenge
Anthony T. Nials, Sorif Uddin
Disease Models & Mechanisms 2008 1: 213-220; doi: 10.1242/dmm.000323

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Alerts

Please log in to add an alert for this article.

Sign in to email alerts with your email address

Article navigation

  • Top
  • Article
    • Abstract
    • INTRODUCTION
    • ACUTE ALLERGEN CHALLENGE MODELS
    • CHRONIC ALLERGEN CHALLENGE MODELS
    • IMPACT OF CHRONIC ALLERGEN CHALLENGE MODELS ON ASTHMA RESEARCH
    • CONCLUSIONS
    • Acknowledgements
    • Footnotes
    • REFERENCES
  • Figures & tables
  • Info & metrics
  • PDF

Related articles

Cited by...

More in this TOC section

  • Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
  • Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis
  • Role of resting metabolic rate and energy expenditure in hunger and appetite control: a new formulation
Show more Commentary

Similar articles

Other journals from The Company of Biologists

Development

Journal of Cell Science

Journal of Experimental Biology

Biology Open

Advertisement

Editor’s Choice – Altered expression of the Cdk5 activator-like protein, Cdk5α, causes neurodegeneration, in part by accelerating the rate of aging

By developing a comprehensive and quantitative metric for physiological age of Drosophila, Edward Giniger and colleagues show that a neurodegeneration mutant produces its effects in part by accelerating the absolute rate of aging.


First Person interviews 

Have you seen our interviews with the early-career first authors of our papers? Recently, we caught up with first authors Sarah Foriel, Henna Myllymäki and Mirja Niskanen, Wenqing Zhou, Rifdat Aoidi and Amy Irving.


Review – Metastasis in context: modeling the tumor microenvironment with cancer-on-a-chip approaches

In a new Review article, Jaap M. J. den Toonder and colleagues evaluate the recent contributions of cancer-on-a-chip models to our understanding of the tumor microenvironment and its role in the onset of metastasis. The authors also provide an outlook for future applications of this emerging technology.


DMM Conference Travel Grants

Are you an early career scientist with plans to attend a scientific meeting, conference, workshop or course relating to the areas of research covered by DMM? The next round of applications for DMM Conference Travel Grants closes on 4 May 2018. Find out more here and get your application in soon.


Why should you publish your next paper in DMM?

DMM aims to promote human health by encouraging collaboration between basic and clinical researchers, covering a diverse range of diseases, approaches and models. Our Editors are all active researchers in the field – your peers, colleagues and mentors, who know how much work has gone into every paper. Recently, we have introduced format-free submission, and we accept peer review reports from other journals, making submission as easy as possible for our authors. Send us your next great paper – publish with us and you'll be in good company.

Articles

  • Accepted manuscripts
  • Issue in progress
  • Latest complete issue
  • Issue archive
  • Archive by article type
  • Subject collections
  • Interviews
  • Alerts

About us

  • About DMM
  • Editors and Board
  • Editor biographies
  • Travelling Fellowships
  • Grants and funding
  • Workshops and Meetings
  • The Company of Biologists

For Authors

  • Submit a manuscript
  • Aims and scope
  • Presubmission enquiries
  • Article types
  • Manuscript preparation
  • Cover suggestions
  • Editorial process
  • Promoting your paper
  • Open Access
  • Biology Open transfer

Journal Info

  • Journal policies
  • Rights and permissions
  • Media policies
  • Reviewer guide
  • Alerts

Contact

  • Contact DMM
  • Advertising
  • Feedback

Twitter   YouTube   LinkedIn

© 2018   The Company of Biologists Ltd   Registered Charity 277992